Pharmaceuticals & Biotech Polish Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Polish Investing Ideas
Celon Pharma's Revenue Set to Soar with 33% Growth in Five Years
New GLP-1 Manufacturing Facility (Europe, launch 2028) Estimated value: +5 PLN per share Celon Pharma’s strategic plan to launch a GLP-1 production facility in Europe by 2028 is a substantial value catalyst. Assumptions include: scalable GMP production tailored to the fastest-growing therapeutic segment globally, attractive economics from contract manufacturing (CDMO) for GLP-1 analogs, strong demand visibility for European supply due to constraints at Novo Nordisk and Eli Lilly, margin uplift from high-value biologics processing.Read more
Expect big change: Nanogroup's NanOX system will tackle global kidney shortages
Overview of Nanogroup and the NanOX Project Nanogroup is focused on addressing the critical shortage of organs for transplantation, particularly kidneys, which are essential for treating end-stage renal disease. The organization has developed an innovative solution known as the NanOX system , designed to improve the availability, preservation, and success rates of kidney transplants.Read more
